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B cell development is a highly regulated process involving multiple differentiation
steps, yet many details regarding this pathway remain unknown. Sequencing of patients with
B cell-restricted immunodeficiency reveals autosomal dominant mutations in TOP2B. TOP2B
encodes a type II topoisomerase, an essential gene required to alleviate topological stress
during DNA replication and gene transcription, with no previously known role in B cell
development. We use Saccharomyces cerevisiae, and knockin and knockout murine models, to
demonstrate that patient mutations in TOP2B have a dominant negative effect on enzyme
function, resulting in defective proliferation, survival of B-2 cells, causing a block in B cell
development, and impair humoral function in response to immunization.
https://doi.org/10.1038/s41467-019-11570-6 OPEN
1 Department of Pediatrics, University of California at San Diego, La Jolla, CA 92093, USA. 2 Rady Children’s Hospital of San Diego, San Diego, CA 92123, USA.
3Division of Genetics and Epidemiology, Institute of Cancer Research, London SM2 5NG, UK. 4 Center for Applied Genomics, Children’s Hospital of
Philadelphia, Philadelphia, PA 19104, USA. 5Department of Medicine, University of California at San Diego, La Jolla, CA 92093, USA. 6 Regeneron
Pharmaceuticals, Inc., Tarrytown, NY 10591, USA. 7 Laboratory of Molecular Immunology, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, CA
92093, USA. 8Department of Pediatrics, Levine Children’s Hospital, Atrium Health, Charlotte, NC 28203, USA. 9Department of Genetics, Children’s Hospital
of Philadelphia, Philadelphia, PA 19104, USA. 10Department of Pediatrics, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA.
11 Institute for Cell and Molecular Biosciences, Newcastle University, Newcastle upon Tyne NE2 4HH, UK. 12German Center for Pediatric and Adolescent
Rheumatology, Garmisch-Partenkirchen 82467, Germany. 13Division of Neonatology, University Hospital for Children and Adolescents, University of Leipzig,
Leipzig 04109, Germany. 14 BGI-Shenzhen, Beishan Industrial Zone, Shenzhen 518083, China. 15 China National GeneBank, BGI-Shenzhen, Jinsha Road,
Shenzhen 518120, China. 16 Institute for Genomic Medicine, University of California San Diego, La Jolla, CA 92093, USA. 17 San Diego Branch, Ludwig Institute
of Cancer Research, La Jolla, CA 92093, USA. 18These authors contributed equally: Christopher D. Putnam, Hal M. Hoffman. Correspondence and requests for
materials should be addressed to L.B. (email: lbroderick@ucsd.edu)
NATURE COMMUNICATIONS |         (2019) 10:3644 | https://doi.org/10.1038/s41467-019-11570-6 | www.nature.com/naturecommunications 1
12
34
56
78
9
0
()
:,;
DNA replication and gene transcription require thattopological stress be relaxed; a critical cellular functionperformed by topoisomerases. Humans possess two genes
that encode type II topoisomerases, TOP2A and TOP2B, which
make transient double-stranded DNA breaks that alleviate
negative supercoils1. Failure to relax topological stress can reduce
the production of multiple gene products, even in the absence of a
genetic mutation. These defects preferentially cause loss of
function of large genes, which are most vulnerable to topologic
stress2,3. To our knowledge, no monogenic disease has been
linked to the inability to relax topological stress.
The study of rare immunodeficiency patients has been extre-
mely instructive to our understanding of B-cell development and
human disease, revealing mechanisms of B-cell development,
central tolerance, and protection from infection4–7. These
immunodeficiencies are primarily characterized by their effects
on the B-cell compartment and typically X-linked recessive (X-
linked agammaglobulinemia) or autosomal recessive7. In contrast,
syndromic immunodeficiencies are a distinct subset of childhood
primary immunodeficiencies in which the physical malformations
are often more pronounced than the underlying immunologic
defects, leading to delays in diagnosis. Chromosomal abnormal-
ities and metabolic defects have been hypothesized to underlie
many multisystem syndromic diseases8. However, the identifica-
tion of single gene in such disorders suggests they likely affect a
shared cellular process that impacts the development of multiple
organ systems.
We previously described two unrelated families with autosomal
dominant inherited syndromic B-cell immunodeficiency of
unknown etiology9,10. While agammaglobulinemia and hypo-
gammaglobulinemia are common to several classic immunode-
ficiencies, the patients were also affected by facial dysmorphism,
and limb anomalies, identifying this as a unique syndrome,
subsequently named Hoffman syndrome, but the genetic etiology
remained unknown until now.
Here, we show that mutations in TOP2B underlie the syn-
dromic B-cell immunodeficiency and investigate how these
dominant genetic defects lead to reduced TOP2B function,
defects in B-cell development, and B-cell activation in response to
antigen stimulation using models in Saccharomyces cerevisiae,
and knockout and knockin murine lines. These results are the
initial description of a role for TOP2B in human immunodefi-
ciency syndromes associated with impaired B-cell development
and function.
Results
Identification of TOP2B mutations. We previously reported two
unrelated families with autosomal dominant inherited syndromic
B-cell immunodeficiency of unknown etiology (Table 1, Supple-
mentary Table 1)9,10. The probands from each family presented
with recurrent infections by polysaccharide-encapsulated bac-
teria, severe hypogammaglobulinemia, and absent CD19+ B cells,
but had normal T-cell responses to mitogens. We performed
whole genome sequencing of affected and nonaffected persons in
these families (Fig. 1a). We filtered variants within each family
assuming that the variants would not be in dbSNP11, would have
a dominant inheritance pattern, and would affect coding
sequences (Supplementary Tables 2–4). One gene, TOP2B, which
encodes topoisomerase IIβ12,13 was affected by a heterozygous
variant in each family: a de novo in-frame deletion
c.1761_1763delAGA, p.EE587E, and a missense mutation
c.1448C > T, p.S483L. A third patient initially being reported as
having an atypical presentation of Ablepharon-Macrostomia
syndrome14, was later found to have humoral immunodeficiency.
Independent reanalysis of clinical whole-exome sequencing
revealed a heterozygous TOP2B variant: c.1897G > A, p.G633S.
All of the mutations affected the TOPRIM domain of TOP2B
(Fig. 1b)15. Notably, TOP2B has a probability of loss of function
intolerance (pLI) of 1 (Supplementary Table 5), similar to most
known severe haploinsufficiency human disease genes16, sug-
gesting that the identified heterozygous mutations in our patients
could cause disease either through haploinsufficiency or a partial
genetic dominance.
Patient mutations inactivate topoisomerase II function. The
patient mutations affected highly conserved amino acids (Sup-
plementary Fig. 1). We tested the ability of patient TOP2B
mutations to complement the temperature sensitivity of the
top2–4 allele of S. cerevisiae TOP2, an essential gene that encodes
the only S. cerevisiae topoisomerase II homolog17. We introduced
the S. cerevisiae equivalents of the patient mutations into a pre-
viously established plasmid encoding a chimeric S. cerevisiae–
human TOP2B fusion, which can complement the top2–4 growth
defect at 37 °C18. Unlike the wild-type construct, chimeric con-
structs containing the patient mutations S483L or EE587E were
unable to complement top2–4 at the nonpermissive temperature,
similar to an empty vector control (Supplementary Fig. 2).
To ensure that patient mutations were not interacting with
some aspect of the Top2–TOP2B protein chimera, we constructed
a low-copy number plasmid containing the S. cerevisiae TOP2
gene (and its native promoter) that contained an artificial intron
to avoid toxicity in Escherichia coli strains (ScTOP2 vector,
Supplementary Fig. 3). Similar to the mutant chimeric constructs
but unlike the wild-type ScTOP2 plasmid, the mutant ScTOP2-
S483L, -EE587E, and -G633S vectors were unable to complement
the top2–4 at the nonpermissive temperature, consistent with a
loss of function (Fig. 2a).
To demonstrate that the disease-associated mutations were
inactive and not just temperature sensitive, we sporulated a
heterozygous top2Δ/TOP2 diploid S. cerevisiae strain that
contained either wild-type or mutant versions of the ScTOP2
vector. We found that the wild-type ScTOP2 vector allowed
robust recovery of top2Δ-containing haploids (Fig. 2b, Supple-
mentary Table 5). No haploid spore clones lacking TOP2 were
recovered with an empty vector control or with the ScTOP2-
EE587E, -S483L, or -G633S vectors (Fig. 2b). Taken together,
these results indicate that each of our patient mutations disrupt
topoisomerase II function.
Mutations have a partial dominant phenotype in S. cerevisiae.
The effects of the heterozygous patient TOP2B mutations could
be due to haploinsufficiency or to the formation of partially
inactive wild-type/mutant TOP2B heterodimers. To test these
possibilities, we isolated a top2Δ haploid containing the wild-type
ScTOP2 vector and introduced a second vector; both vectors were
present at the same copy number (Supplementary Fig. 4a).
Growth analysis demonstrated that the strains with ScTOP2-
EE587E or ScTOP2-S483L grew more slowly than the wild-type
controls (Fig. 2c), but were not associated with the activation of
the DNA damage checkpoint (Supplementary Fig. 4b). Nuclear
fractions derived from these strains were tested for Top2-
dependent decatenation activity. Remarkably, fractions from the
strain with only one copy of wild-type TOP2 decatenated kine-
toplast DNA more effectively than fractions from strains with one
wild-type and one mutant copy of TOP2 (Fig. 2d, Supplementary
Fig. 4c). Thus, the disease-associated versions of TOP2 have a
partial dominant negative phenotype in S. cerevisiae based on
growth and/or decatenation assays.
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Loss of TOP2B negatively affects the B-cell compartment.
Affected patients have a normal T-cell compartment, but lack
B cells in the peripheral blood1,2. Notably, patients also have
dramatically reduced but detectable levels of circulating immu-
noglobulins (Table 1), suggesting that B cells in the patients are
substantially reduced, but may not be entirely lost. To test the role
of TOP2B in B-cell development, we bred Top2bflox2 mice to two
independent B cell-specific cre mice: cd19-cre19 and mb1-cre20, as
Top2b−/− mice do not survive the perinatal period21. Flow cyto-
metry of peripheral blood demonstrated that Top2b−/−mb1-cre
and Top2b−/−cd19-cre mice had fewer CD19+ B cells than
wild-type controls (Fig. 3a, Supplementary Fig. 5a). The
Top2b−/−cd19-cre mice were less severely impaired, suggesting
that Top2b plays a role earlier in the B-cell lineage than is affected
by the cd19-cre transgene20. Therefore, we focused on our
Top2b−/−mb1-cre model.
Immunocytochemical evaluation of Top2b−/−mb1-cre mice
showed altered splenic follicle structure, with reduced marginal
zone and follicular B-cell zones (Fig. 3b–j), suggesting that Top2b
promotes B-cell development. To further characterize these
differences, we examined spleen and bone marrow from
Top2b−/−mb1-cre and control mice for conventional B cells by
flow cytometry. Immunophenotyping demonstrated that the bone
marrow of Top2b−/−mb1-cre mice have fewer PrePro B cells, Pre
B, and immature B cells compared to control mice (Fig. 3K). In
the spleen, there were fewer B cells at every developmental stage
compared to control mice (Fig. 3l). Analysis of kappa-deleting
recombination excision circles (KRECs)22 demonstrated that B
cells derived from Top2b−/−mb1-cre mice had fewer KRECs
compared to controls in the spleen and bone marrow (Fig. 3m
and Supplementary Fig. 5b), suggesting a reduced replication
history. Furthermore, expression of Pax5, a B-cell specific
transcription factor expressed at most stages of B-cell develop-
ment23–25, was significantly reduced in B cells derived from
Top2b−/−mb1-cre mice while Rag1 expression was unchanged
(Fig. 3n, o). Together, these data suggest B-cell specific defects
caused by the absence of Top2b may occur due to transcriptional
defects affecting multiple stages of B-cell development.
B cells fail to activate normally in the absence of Top2b. To test
the role of Top2b in humoral immunodeficiency and antigen-
specific responses, Top2b−/−mb1-cre and littermate control mice
were immunized with ovalbumin (OVA). Fourteen days after
immunization, serum samples from control mice demonstrated
increased OVA-specific IgG, which was not observed in
Top2b−/−mb1-cre mice (Fig. 4a). To determine if this defect was
OVA-specific, mice were immunized with polysaccharide antigen
Pneumovax-23 (PPV23)26,27. There was no difference in PPV23
binding IgM at zero or 6 days post-immunization between
Top2b−/−mb1-cre and control mice, and B-1 cells in the bone
marrow and spleen were unaffected (Fig. 4c, Supplementary
Fig. 5c, d). Similar to OVA immunization, anti-PPV23 IgG3
Table 1 Immunologic laboratory values at time of diagnosis of patients with TOP2B mutationsa
Family 1 Family 2 Family 3
Age at presentation 7 years 35 years 6 years 5 years
General immune evaluation
Leukocytes (cells/μL) 5200 7600 7000 5900
[4500–13500] [4000–1000] [5500–15,000] [5500–15,000]
Absolute Lymphocyte count (cells/μL) 1900 2000 2240 3547
[1500–6500] [1200–3500] [1500–7000] [1500–7000]
CD3+ T cells (cells/μL) 1853 1764 2720 3422
[1200–2700] [1100–2500] [1900–3000] [1400–3700]
CD4+ T cells (cells/μL) 1122 1008 1728 1832
[800–1500] [700–1400] [570–1200] [700–2200]
CD8+ T cells (cells/μL) 774 726 800 1417
[400–1200] [400–1100] [475–960] [490–1300]
CD19+ B cells (cells/μL) 0 48 0 0
[150–600] [150–500] [200–600] [200–600]
CD16+ NK cells (cells/μL) 58 172 448 17
[200–400] [150–400] [200–600] [200–600]
CH50 n.d. n.d. 90 >65
[n.a.] [n.a.] [>80] [>60]
B cell-specific immune evaluation
Total IgG (mg/dL) 232 631 73 242
[610–1480] [720–1460] [400–1075] [463–1236]
IgA (mg/dL) <26 158 33 7
[40–290] [24–381] [19–119] [25–154]
IgM (mg/dL) 150 128 12 <6
[380–1860] [54–227] [25–114] [43–196]
IgE (mg/dL) n.d. n.d. 5 n.d.
[n.a.] [n.a.] [0–450] [n.a.]
tetanus titerb (IU/mL) deficient n.d. <0.04–> 0.11 0.1
[>0.15] [n.a.] [>0.15] [>0.15]
Diphtheria (IU/mL) titers deficient n.d. undetectable <0.1
[>0.15] [n.a.] [>0.15] [>0.15]
H. influenzae B titers (ng/mL) deficient n.d. undetectable <0.15
[>0.15] [n.a.] [>100] [>0.15]
Mitogen stimulation normal normal normal normal
aNormal values for age, per reference lab, shown in square brackets. n.d. not done, n.a. not available
bTiter values are expressed as expected postimmunization9,10
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trended downwards, and anti-PPV23 IgG2b was significantly
reduced in Top2b−/−mb1-cre mice compared to controls at
6 weeks post-immunization (Fig. 4c, d). The immunization
responses in the Top2b−/−mb1-cre mice are consistent with the
failure to mount a vaccine response observed in patients.
Since the antigen-specific responses could reflect depletion of B
cells in Top2b−/−mb1-cre mice in addition to any B-cell
activation defects, splenic B cells were isolated and stimulated
in vitro with lipopolysaccharide (LPS). After 72 h of stimulation,
Top2b−/− mb1-cre derived B cells failed to proliferate and had
increased cell death compared to their wild-type counterparts
(Fig. 4e–g). In addition, surviving Top2b−/− mb1-cre B cells had
less robust upregulation of the activation marker MHC II
(Fig. 4h). Together these results suggest that the defects in
antigen-specific responses in the absence of Top2b are due to
both reduced numbers of B cells as well as defects in the secretion
of antibody or in the generation of mature, activated B cells.
Mutant Top2b negatively affects B-cell development in mice.
To evaluate the effects of mutant Top2b expression on the B-cell
compartment in mice, we generated a constitutive knockin mouse
carrying the murine equivalent of the TOP2B mutation EE587E.
Top2bEE587E/EE587E homozygous mice were not viable, similar to
Top2b−/− mice, but Top2b+/EE587E heterozygotes could be
recovered, which mirror the genotype of the Hoffman syndrome
patients (Supplementary Table 7). Several observations indicated
the presence of B cell defects in the Top2b+/EE587E mice relative to
wild-type controls: (1) the spleen-to-body ratio was reduced
(Fig. 5a); (2) total serum IgG was reduced (Fig. 5b); (3) immu-
nization with ovalbumin or Pneumovax-23 generated sig-
nificantly lower titers of antigen-specific antibody (Fig. 5c, d); and
(4) flow cytometric immunophenotyping of the bone marrow and
spleen demonstrated reduced numbers of B cells at most stages of
B-cell development (Fig. 5e, f, Supplementary Fig. 6a). Thus, even
heterozygous expression of the patient-derived Top2b mutation
had deleterious effects on the B-cell compartment that were
comparable to the effect of the Top2b−/−mb1-cre mice.
Patients have normal numbers of CD4 and CD8 T cells, but no
detectable peripheral B cells in blood (Table 1), despite cells
originating from a common lymphocyte precursor. Since defects
in TOP2B give rise to reduced transcription of long genes2,3, we
investigated the expression of transcription factors involved in
establishing and/or maintaining B- and T-cell fate. Rag1 and E2A,
genes required for both B- and T-cell development, were similarly
Total SNP & INDEL
Not observed in dbSNP
Dominant inheritance &
not observed in unaffected
Coding variants
Common gene
TOP2B
a Family 1 Family 2 Family 3
G633S
c
b
DNA
DNA
G633S
EE587E
EE587E
S483L
S483L
EE587ES483L
G633S
G633S
8,158,579 12,309,661
179,830 265,957
11,860 23,575
70 115
1
α4 helix
Winged helix
domain
ATPase
S483L EE587E
TOPRIM DNA binding CTD
Fig. 1 Mutations in TOB2B cause peripheral B-cell immunodeficiency and dysmorphic features. a Pedigrees in three unrelated families with variants in
TOP2B. Filled symbols, subjects with mutation; open symbols, unaffected subjects. Arrows indicate individuals subjected to whole genome sequencing.
Three variants were identified: a missense mutation c.1448C > T, p.S483L, a de novo inframe deletion c.1761_1763AGAdel p.EE587E, a missense mutation
c.1897G > A, p. G633S. b Modeling of the identified variants in protein domains. Linear modeling shows the approximate location of patient mutations in
the TOPRIM domain. c 3D modeling with green and blue helices representing two domains of the homodimer, and black and white spheres representing
the DNA helix in the binding site. Mutations are displayed in red in the structure of the TOPRIM domain
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expressed in bone marrow derived lineage-negative CD117-
negative progenitor cells between mutant and wild-type mice
(Fig. 5g, h). However, pre-B cells from Top2b+/EE587E mice
demonstrated reduced expression of the B cell-specific transcrip-
tion factors Pax5 and Foxo1 (Fig. 5I, J). Unlike the B cell-specific
transcription factors, expression of the T cell-specific transcrip-
tion factors Notch1 and Tcf1 in the spleen was similar to
littermate controls (Supplementary Fig. 6b, c).
Mutant Top2b has a dominant negative effect on B cells. To
determine if disease phenotype is due to haploinsufficiency or due
to dominant negative behavior of the mutation as observed in our
S. cerevisiae models, we compared Top2b+/EE587E mice to
Top2b+/− mice. Similar to patient proband A, Top2b+/EE587E
mice had decreased peripheral blood B cells, which were reduced
even compared to Top2b+/−mice, without an effect on peripheral
blood T cells (Fig. 6a, b). In addition, KRECs were reduced in the
Top2b+/EE587E mice, while T-cell receptor excision circles
(TRECs) were unaffected (Fig. 6c, d), suggesting reduced pro-
liferation of B cells with equivalent T-cell proliferation.
Since Top2b defects could directly or indirectly give rise to
unrepaired DNA breaks, we analyzed cells using a single-cell
comet assay. Splenic B cells isolated from Top2b+/EE587E mice had
increased DNA breaks compared to B cells from Top2b−/− mb1
cre and wild-type mice as measured by the increase in comet tail
length (Fig. 6e, f), while the comet tail length was not altered in
T cells derived from Top2b mutants (Fig. 6g). To assess this B
cell-intrinsic effect, expression analysis of WT mouse Top2b at
the transcript and protein level was performed. B cells have
greater expression of Top2b mRNA and protein compared to
T cells (Fig. 6h, i), which is consistent with previous reports in
both humans and mice28–31. Together these results suggest that
Top2b is more active in B cells than in T cells.
Heterozygous mutant B cells fail to secrete antibodies. The
Top2b+/EE587E heterozygous mice recapitulated the Hoffman
syndrome patient defects in peripheral blood B cells without an
effect on peripheral blood T cells (Fig. 6a, b; Table 1). To
determine whether the remaining B cells in the heterozygous
mice were functional, we compared in vitro activation of mutant
B and T cells. In response to in vitro stimulation with LPS with or
without IL-4, Top2b+/EE587E derived B cells demonstrated
decreased secretion of total IgG, IgG3, and IgG2b compared to
littermate controls (Fig. 7a, Supplementary Fig. 7a, b). In contrast,
in vitro stimulation of isolated splenic T cells showed similar IL-2
production in response to PMA and ionomycin in both
Top2b+/EE587E mice and controls (Fig. 7b). These results are
consistent with the normal T-cell mitogen stimulation results
observed in the patients (Table 1).
B cells in Top2b heterozygotes have proliferation defects. B-cell
proliferation and cell death has been modeled as a stochastic
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response during development and following antigenic stimula-
tion32,33. Since Top2b is expressed at all stages of the cell cycle34,
we asked whether Top2b affects the likelihood of stimulated
B cells to proliferate rather than to undergo cell death. After three
days in culture, stimulated mutant B cells were reduced in
number (Fig. 7c), and had greater lactate dehydrogenase (LDH)
release in response to LPS stimulation, compared to wild-type
controls (Supplementary Fig. 7c). T-cell proliferation was unaf-
fected (Fig. 7d). Splenic derived B cells were then cultured with
LPS and IL-4 to enhance the rate of proliferation35 and assessed
by CFSE dilution and propidium iodide to determine if mutant
B cells were defective in cell division. After 5 days in culture, the
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majority of viable wild-type B cells had undergone 3–4 rounds of
division, while more than 90% of mutant B cells did not advance
beyond the first division (Fig. 7c, Supplementary Fig 7d.) Toge-
ther these results further support a role for mutant Top2b in
B cells, leading to an increased propensity to undergo apoptosis
rather than cell division.
Discussion
Genetically defined immunodeficiencies were first described with
the identification of BTK mutations in X-linked (Bruton’s)
agammaglobulinemia36,37, and subsequently expanded to include
several B-cell receptor genes, including BLNK, µ heavy chain, and
CD79A/B5,38. Given the complexities of B-cell development,
numerous other genetic defects likely remain to be revealed. In
three families with Hoffman syndrome9,10, we identified three
heterozygous mutations affecting the TOPRIM, or DNA gating,
domain of the type II topoisomerase TOP2B. Introduction of
these mutations into S. cerevisiae indicate that the mutations are
partially dominant loss-of-function mutations, consistent with
the nonviability of the homozygous Top2bEE587E/EE587E mice.
Both the Top2b−/− conditional knockout mouse model and the
Top2b+/EE587E heterozygous mouse model exhibit immunological
defects affecting B cells, but not T cells, which correlate with the
immunodeficiency observed in Hoffman syndrome patients and
support that the TOP2B mutations underlie this syndrome. Thus,
Fig. 3 B-cell development is negatively affected in the absence of TOP2B. a Absence of TOP2B in B cells results in reduced CD19+ B cells in peripheral blood
compared to littermates (n= 6 WT and 7 Top2b−/− mb1 cre mice per group, mean ± SEM, ****p < 0.0001). b Splenic white pulp subcompartments are
reduced in size in the absence of Top2b. Area of three sub-compartments were evaluated in at least ten follicles across three sections (500 μM apart) with
marker indicating average per mouse. (Mean SEM, *p < 0.05). Representative follicles from wildtype (c–f) and Top2b−/− mb1-cre spleens (g–j) show
altered splenic architecture. More B220-expressing (red) cells are seen in the wildtype (c, f) than Top2b−/− mb1-cre mice (g, j). The metallophilic
macrophages (blue) indicating the border between marginal zone and follicular region. The periarteriolar lymphoid sheath (PALS) subcompartment
contains T cells (green). Scale bar indicates 200 µm. Bone marrow (k) and spleen (l) cells were isolated from wildtype and Top2b−/− mb1-cre mice. Flow
cytometry demonstrates that the bone marrow of Top2b−/− mb1-cre mice have fewer PrePro B cells (Fr. A, B220+, CD43−, BP1−, CD24−), Pre B cells
(Fr. D, B220+, CD43−, IgD−, IgM−), and immature B cells (Fr. E, CD19+, B220+, CD43−, IgM+, IgD−) compared to controls (k). In the spleen (l), there
are overall fewer B cells with reductions in marginal zone precursors (CD19+, B220+, IgMhi, IgDhi, CD21/35+), follicular (CD19+, B220+, IgMlo, IgDhi,
CD38+), and activated (CD19+, B220+, IgDhi, IgMhi, Flt3+) B cells compared to controls. (n= 4 mice per group, mean ± SEM, absolute numbers
calculated from whole tissue numbers). *p < 0.05; **p < 0.01. m qPCR analysis of kappa-deleting recombination excision circles demonstrate that B cells
isolated from Top2b−/− mb1-cre mice have reduced replication in the spleen (n= 6 WT or 9 Top2b−/− mb1 cre mice, shown as mean ± SEM). *p < 0.05.
n Pax5 is significantly decreased in B cells isolated from Top2b−/− mb1-cre mice (n= 9 WT or 6 Top2b−/− mb1- cre mice), whereas Rag1 expression (o) is
unchanged (n= 5 WT and 4 Top2b−/− mb1- cre mice per group shown as mean ± SEM, with technical triplicates), **p < 0.005). All by two-tailed Student’s
t test
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Fig. 4 B cells are functionally impaired in the absence of Top2b, in vivo and in vitro. a Mice fail to produce specific IgG antibody in response to vaccination
with ovalbumin (OVA) in the absence of Top2b in B cells (n= 9 mice per group, shown as mean ± SEM, ***p < 0.005 by the Kruskal–Wallis test).
b–d Adult Top2b−/− mb1 cre and littermate mice were immunized with Pneumovax-23 (PPV23). At 6 days post-immunization (b), B cells produce PPV23-
specific IgM in the absence of TOP2B, at similar levels to wild-type control mice. Four weeks after immunization with Pneumovax-23, anti-PPV23 IgG3
(c) and IgG2b (d) production is impaired in Top2b−/− mb1-cre mice compared to wild-type control animals (n= 6 WT or 5 Top2b−/− mb1 cre, shown as
mean ± SEM, *p < 0.05 by the Kruskal–Wallis test). e In vitro, Top2b−/− mb1 cre mouse-derived B cells fail to proliferate, as assessed by CFSE dilution, in
the presence of stimulation with LPS (blue histogram). Untreated, CFSE stained cells are shown in red. FACS plots are representative of 4 mice per group.
Total number of CFSE positive cells is quantified in (f). g Top2b−/− mb1-cre mouse-derived B cells have increased cell death as measured by LDH release
(n= 7 WT or 8 Top2b−/− mb1 cre mice per group, in duplicate, shown as mean ± SEM). *p < 0.05, two-tailed Student’s t test. h The B cells that do survive
have reduced upregulation of the activation marker MHC II, as shown by mean fluorescence intensity (MFI). *p < 0.05, two-tailed Student’s t test (n= 4
mice per group)
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Fig. 5 B cell development is negatively affected whenTOP2B is mutated. a Spleen to body weight ratio for wild-type (n= 3), Top2b−/−-mb1 cre (n= 3), and
Top2b+/EE587E mice (n= 4) reveal smaller ratios in knockin and knockout mice compared to controls (shown as mean ± SEM). *p < 0.05 by Kruskal–Wallis
test. b Total serum IgG is reduced in Top2b−/− mb1 cre mice (n= 6) and Top2b+/EE587E (n= 4) mice compared to controls (n= 7, shown as mean ± SEM).
*p < 0.05 by Kruskal–Wallis test. c, d Heterozygous mutant mice fail to produce specific IgG antibody in response to vaccination with ovalbumin (OVA,
n= 4, (c) or pneumovax-23 (d) (n= 3 mice per group, shown as mean ± SEM, *p < 0.05 by the Kruskal–Wallis test). Bone marrow (e) and spleen
(f) cells were isolated from Top2b+/EE587E mice and littermate controls. Phenotypic analysis by flow cytometry demonstrates that the bone marrow of
Top2b+/EE587E mice (n= 3) have fewer PrePro B cells (Fr. A, B220+, CD43−, BP1−, CD24−), Pre B cells (Fr. D, B220+, CD43−, IgD−, IgM−), and
immature B cells (Fr. E, CD19+, B220+, CD43−, IgM+, IgD−) compared to control mice (e). In the spleen (f), there are overall fewer B cells with
significant reductions in transitional (CD19+, B220+, IgDlo, IgM+, CD21/35int, CD23 variable), follicular (CD19+, B220+, IgMlo, IgDhi, CD38+) and
activated (CD19+, B220+, IgDhi, IgMhi, Flt3+) B cells compared to control mice (n= 4, shown as mean ± SEM, absolute numbers calculated from whole
tissue numbers). *p < 0.05; **p < 0.01, two-tailed Student’s t test. Expression of mutant Top2b results does not affect E2A (g, n= 6)) or Rag1 (h, n= 8)
expression in common lymphoid progenitor cells (compared to WT n= 6), whereas B cell-specific transcription factors Pax5 (i) and Foxo1 (j) show reduced
expression of compared to wild-type mice. (n= 4 mice per group, shown as mean ± SEM, *p < 0.05, two-tailed Student’s t test)
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Fig. 6 Heterozygous mutation in Top2b negatively affects B-cell development beyond haploinsufficiency. Expression of mutant Top2b (n= 7) results in
reduced CD19+ B cells (a) in peripheral blood compared to wild-type (n= 6) or hemizygous mice (n= 6), while T cells (b) are unaffected.(shown as
mean ± SEM, *p < 0.05, **p < 0.005, two-tailed Student’s t test). c qPCR analysis of kappa-deleting recombination excision circles demonstrates that B cells
isolated from Top2b+/EE587E (n= 7) or Top2b+/− mice (n= 7) have a less robust replication history compared to wild-type mice (n= 8 mice), shown as
mean ± SEM, while T-cell proliferation as measured by T-cell receptor excision circle (TREC) formation is unaffected (d), (n= 6 WT, 6 mutant and 4
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shown as mean ± SEM, *p < 0.05, two-tailed Student’s t test), and immunoblot (i, protein isolated from B and T cells from three wild-type mice,
representative of four experiments; source data are provided as a Source Data file)
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our findings define a class of B-cell immunodeficiency and are the
first description of a defined monogenic syndrome due to
mutations in the essential gene TOP2B.
Defects in Top2b in mice give rise to a unique B-cell defect.
Unlike mutations in genes like BTK or PIK3R1, which give rise to
a failure of cells to progress past a distinct stage in B-cell devel-
opment39, loss of Top2b function in mice gives rise to reduced
levels of B cells in multiple stages of B-cell development and
defects in the production of specific immunoglobulins when
challenged with antigens. Consistent with this, Top2b is highly
expressed in B cells, and Top2b+/EE587E and Top2b−/− mb1 cre
mice have much lower levels of expression of B cell-specific
transcription factors, including Pax5. The relative loss of Pax5
specifically would favor proximal gene usage, resulting in a
reduced V gene repertoire, without affecting T-cell
development40. Top2b is expressed at much lower levels in T cells,
with numbers of T cells and T cell-specific transcription
factor expression similar between wildtype, Top2b+/EE587E and
Top2b−/− mb1 cre mice. In addition to reduced B cell numbers,
B cells from Top2b+/EE587E mice respond poorly to stimulation,
producing less total IgG, IgG3, and IgG2 in response to LPS or
LPS+ IL-4. Mutant B cells also fail to proliferate or undergo cell
death after stimulation; whereas T cells derived from Top2b
+/EE587E mice responded normally to PMA and ionomycin.
Thus, defects in Top2b not only affect the number of mature B
cells that survive checkpoints during development, but also the
ability of the mature B cells to properly respond to stimulus.
Hoffman syndrome patients have no detectable B cells in the
peripheral blood, nor form germinal centers, and patients did not
generate protective serologic titers to immunization9; however,
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detectable amounts of circulating immunoglobulins indicate that
some B cells are present, but are below the clinical limits of
detection. In contrast, patients show normal numbers of CD4+
and CD8+ T lymphocytes and T-cell mitogen stimulation. These
observations are consistent with the profound defects in B-cell
numbers and stimulus response but normal T cells seen in the
Top2b mutant mice. A bone marrow biopsy has not been clini-
cally indicated for patients, leaving open the question of where in
B-cell development the failure occurs in humans; however, the
analysis of the Top2b mutant mice suggests that in the absence of
functional TOP2B, the bone marrow generates a reduced B cell
compartment and that the remaining surviving cells have reduced
ability to respond to antigen or general stimuli. While our murine
model has some phenotypic differences from our patients, it does
provide opportunities to study B cells, which are not detected or
practically assessed in our human patients.
TOP2B defects specifically cause a profound loss of the B-cell
compartment and B-cell function. One possible explanation for
this specificity is that long gene transcription is preferentially
reduced when topoisomerases are absent or inhibited2,3, and that
the murine B-cell transcription factors are notably longer (EBF is
390 kb, Pax5 is 178 kb, and Foxo1 is 85 kb) compared to T-cell
transcription factors (Tcf1 is 30 kb and Notch1 is 45 kb) or shared
transcription factors (Rag1 is 11 kb and E2A is 24 kb). Consistent
with this, TOP2B is more highly expressed in B cells than in
T cells in both humans and mice (Fig. 6h, i)28–31.
Topoisomerases act to prevent the generation of free DNA
breaks during transcription. In our murine models, the most
obvious reduction in B cell numbers occurs during V(D)J
recombination in the bone marrow, and during class switch
recombination in the in vitro studies. The order of immunoglo-
bulin gene rearrangement in B cells is predetermined, with heavy
chain rearrangement preceding light chain rearrangement41. An
inability to accurately form double strand breaks, failure to repair
them or effectively pair recombination signal sequences would
also be associated with inability to proliferate past the first
replication. While these recombination defects can lead to
immunodeficiency42,43, we might expect a greater tendency to
malignancy, which has not been observed in our patients or mice.
TOP2B is also involved in transcriptional regulation during
differentiation44,45 through association with multiple transcrip-
tion factors, CTCF, and cohesin at transcriptional domain
boundaries46,47 Analysis of published Top2b ChIP-seq data and
etoposide-induced DNA breaks as determined by END-seq from
murine primary B cells48 showed the presence of Top2b (but not
Top2a) in the promoter and enhancer (intron 5) regions of Pax5
(Supplementary Fig. 8). CTCF binding has also been described at
multiple sites within the murine Igh locus, where it is required for
distal gene usage with Pax5 and cohesion subunit Rad21, in a
stage specific fashion49. Impairments in germline transcriptional
activity, caused by defective Top2b activity could affect Igh locus
accessibility, with negative effects on V(D)J recombination50.
Similarly, in human cell lines, CTCF binding is prominent in the
promotor and enhancer regions. The reduced numbers of NK
cells in two of the patients (Table 1) may be consequent to similar
binding patterns of Top2b to the Nfil3 promoter, a regulator of
NK cell differentiation51–53.
Given the potential for transcriptional defects to affect multiple
organs, it is not surprising that other features characterize chil-
dren with this syndrome since Top2b promotes correct expres-
sion of developmentally regulated genes45,54,55. We cannot,
however, rule out the possibility that the TOPRIM domain
mutations might also allow DNA breaks to accumulate. Con-
sistent with this latter possibility, a brief clinical report recently
described a patient with progressive microcephaly, developmental
delay, and hypotonia, who had a variant outside of the TOPRIM
domain of TOP2B (H58Y)56. However, no similarities to our
patients were identified and it is currently unclear if this variant is
causative. While beyond the scope of this manuscript, we expect
these insights will ultimately help in unraveling the mechanism
underlying the various aspects of Hoffman syndrome.
Methods
Human subjects. Blood samples were obtained from the affected patients and their
immediate family members. All participants, or parents or legal guardians if the
patient was a minor, provided written informed consent under protocols approved
by the UCSD and/or CHOP Institutional Review Boards for participation in
research and publication of data.
DNA isolation, library construction, and sequencing. For families 1 and 2,
genomic DNA was isolated from blood by the QIAGEN DNA extraction kit and
randomly fragmented. Fragments of the desired length were gel purified. Adaptor
ligation and DNA cluster preparation were performed with the library preparation
kit per the manufacturer’s instruction (Illumina, San Diego). Whole genome
sequencing was performed at Beijing Genomics Institute with the Illumina
HiSeq2000 platform to a mean, per-sample depth of 30×.
Sequence analysis. For families 1 and 2, all raw 100 bp paired-end reads were
aligned to the human genome reference sequence (hg19) using BWA v0.5.9-r1657
with default parameters for paired-end reads except for seed length (-l) set to 35.
Aligned reads were realigned using GATK’s58 IndelRealigner v 1.6-9-g47df7bb.
Duplicate reads were removed using Picard Tools v 1.69 MarkDuplicates [http://
picard.sourceforge.ne]. Finally, the GATK’s TableRecalibration tool was used to
recalibrate the reads’ base quality scores. (Supplementary Tables 2 and 3).
SNPs and indels were called using GATK v 1.6-5-g557da77 UnifiedGenotyper
with parameters -stand_call_conf 20.0, -stand_emit_conf 10.0, and -dcov 2000.
UCSC assembly hg19 and dbSNP13711 were used as references. The called variants
were recalibrated using the same GATK modules, VariantRecalibrator and
ApplyRecalibration. SNPs and Indels were recalibrated separately as recommended
by GATK’s best practices. For SNPs, we used the references HapMap v3.3, 1000G
Omni2.5, and dbSNP137 and the annotation options QD, HaplotypeScore,
MQRankSum, ReadPosRankSum, FS and DP during the VariantRecalibrator step.
For Indels, we used the reference Mills 1000G gold standard indels from GATK
and the annotation options DP, FS, ReadPosRankSum, MQRankSum, and
HaplotypeScore during the VariantRecalibrator step. We then set the tranch filter
level to 99 and 95 for SNPs and Indels, respectively. Since all samples were females,
we removed variants called on the Y chromosome.
Variants were queried against dbSNP137 to determine novel or known variants.
Next, we used snpEff59 v. 2.0.5 in combination with GATK VariantAnnotator, both
with default parameters, to identify the different the functional and impact on
coding genes (Supplementary Tables 3 and 4).
To identify variants that could be causal we applied the following filters: (1) the
variant must have passed all variant calling filters, (2) the variant is not in
dbSNP137, (3) the genotype was not called “undetermined” by GATK for any of
the 5 samples (gt equal “./.”), (4) for Family 1, we removed any variant that was
called reference in either of the samples or if it was called alternate in either of the
unaffected controls in Family 2, and (5) for Family 2, we removed any variant that
was called reference in the affected patient or nonreference in the unaffected
controls. After applying the filters to select for a causal variant, there was only 1
gene with nonsynonymous changes in only the affected patients in both families,
TOP2B (Fig. 1a).
For Family 3, after informed consent was obtained, the patient was recruited
under research protocol approved by the institutional review board of the
Children’s Hospital of Philadelphia. The sequencing was performed in a clinical
laboratory and the resulting data were fed into our pipeline to exclude synonymous
variants, variants with minor allele frequency greater than 0.5% in either the 1000
Genomes Project or the 6503 exomes from the National Heart, Lung, and Blood
Institute Exome Sequencing Project (ESP6500SI), variants previously identified in
controls by our in-house exome variant database (greater than 4000 individuals),
and variants that were predicted by SIFT/PolyPhen-2 scores to be benign. After
filtering, no potential candidate gene with paired mutations was identified. To
facilitate identification of de novo dominant variants, we then presumed that the
variants responsible for the disease would be extremely rare and probably absent in
the general population due to the severity of the phenotype. Therefore, we selected
for variants not present in 1000 Genomes Project, ESP6500SI, ExAC v0.3, and not
identified in subjects by our in-house exome variant database. A variant in TOP2B
was identified as the most likely candidate.
For all three families, mutations in TOP2B were confirmed by Sanger
sequencing.
S. cerevisiae strains. S. cerevisiae experiments used strains JN394t2-460,
RDKY2325 (MATa ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2Δ202), RDKY2326
(MATα ura3-52, leu2Δ1, trp1Δ63, his3Δ200, lys2Δ202), and RDKY3590 (MATa
ura3-52, leu2Δ1, trp1Δ63, hom3-10, lys2::InsE-A10) were a gift from RD Kolodner
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(UCSD). Strains RDKY9075 (MATα hom3-10, ura3 Δ0, leu2Δ0, trp1Δ63, his3Δ200,
lyp1::TRP1, cyh2-Q38K, iYFR016C::PMFA1-LEU2, can1::PLEU2-NAT, yel072w::
CAN1-URA3, HUG1-EGFP::hphNT1, trp1::kanMX4), RDKY9073 (MATa his3Δ0
leu2Δ0 met15Δ0 ura3Δ0 HUG1-EGFP::hphNT1) and RDKY8176 (MATα hom3-10,
ura3Δ0, leu2Δ0, trp1Δ63, his3Δ200, lyp1::TRP1, cyh2-Q38K, iYFR016C::PMFA1-
LEU2, can1::PLEU2-NAT, yel072w:: CAN1-URA3, HUG1-EGFP::hphNT1, rad27::
HIS3) were a gift from Binzhong Li and RD Kolodner (UCSD). The heterozygous
top2 diploid strain LBY0039 (MATa/MATα ura3-52/ura3-52, leu2Δ1/leu2Δ1,
trp1Δ63/trp1Δ63, his3Δ200/his3Δ200, lys2Δ202/lys2Δ202, top2::G418/TOP2) was
constructed by crossing RDKY2325 and RDKY2326 and knocking out one copy of
TOP2 by PCR-based gene disruption using standard techniques61,62. Derived
strains are summarized in Supplementary Table 9.
S. cerevisiae plasmids. Plasmids containing a chimeric YTOP2-TOP2B fusion in
which the first five residues of yeast TOP2 are fused to residues 46–1621 of human
TOP2B18,60, or YTOP2 were used. To avoid the toxicity of the S. cerevisiae TOP2 in
E. coli during plasmid propagation, an intron was inserted into the catalytic site of
YTOP2, with the sequence GTATGT_gattttgaggctgtaacaattttctttcttttaaaaaaatgattaa
gttgaa_CACTAAC_atagtagaatcttca_CAG, modified from the MCM21 intron
(Supplementary Fig. 3)63. The length of 82 base pairs is not evenly divisible by 3,
resulting in no possible readthrough without frameshift64. In addition, this modified
MCM21-PacI intron has stop codons in all three reading frames. Briefly, genomic
DNA was cloned from RDKY3590 using the following primers A: 5′-ACT CCA
ACG TCA AAG GGC GAA AAA CCG TCT ATC AGG GCG ATG GCC CAC
TAC CCG CGG AGG AAC CAG GGG CTA ACT GT-3′, B: 5′-GTC GAC gat tta at
cat TTA ATT AAa aga AAG AAA ATT GTT ACA GCC TCA AAA TCA CAT
ACC TTC TGT CAG AAC TAA AGT AC-3′; C: 5′-CCG CGG gat tct tTT AAT
TAA atg att aag ttg aaC ACT AAC ata gta gaa tct tca CAG GGG ATT CCG CCT
TGT CAT TAG-3′, D: 5′-GTG AAC CAT CAC CCT AAT CAA GTT TTT TGG
GGT CGA GGT GCC GTA AAG CAC TGT CGA CTT CTC GGG CAG ATC TTT
GT-3′. Fragments AB (5′) and CD (3′) were separately cloned into pCR2.1-TOPO
via the manufacturer’s specifications. The 5′ and 3′ portions of TOP2 with intron
were ligated, and subcloned into the ARS-CEN plasmid pRS31465. The presence of
the intron in each of the plasmids was verified by sequencing by Eton Bioscience,
Inc. (San Diego, CA). Mutations equivalent to the patient-identified mutations were
introduced into the plasmids (Supplementary Table 8).
S. cerevisiae complementation studies. Temperature sensitive strain JN394
top2–466 was transformed with plasmids containing wild-type TOP2, top2 mutant,
or empty vector pRS31462. Yeast strains were grown in selective liquid culture at
25 °C, serially diluted and replica plated. Plates were incubated at 25 °C or 37 °C
and viability assessed.
S. cerevisiae sporulation. The diploid strain LBY0039 (MATa/MATα ura3-52/
ura3-52, leu2Δ1/leu2Δ1, trp1Δ63/trp1Δ63, his3Δ200/his3Δ200, lys2Δ202/lys2Δ202,
top2::G418/TOP2) was transformed with one of the vectors: ScTOP2, ScTOP2-
EE587E, ScTOP2-S483L, ScTOP2-G633S, pRS314. Strains were sporulated in
nitrogen-deficient starvation medium using standard techniques, and random spores
isolated by lysing cells in 50 μl 1 mg/ml lyticase followed by incubating for 30min at
37 °C. Spores were resuspended in sterile water, vortexed in Eppendorf tubes to
adhere random spores to the walls of the plastic tubes, and washed with sterile water.
Washed spores were resuspended in 1.5% NP40 and spread on nonselective YPD
plates. Spore clones were then genotyped for growth on CSM–TRP medium (presence
of the pRS314-derived vector), YPD+ 200 μg/mL G418 medium (presence of geno-
mic top2::G418), and for mating type (Supplementary Table 6). When diploid strains
containing the empty vector or top2mutant vectors were sporulated, a fewMATa and
MATα spores (n= 6–9) were observed that were tryptophan prototrophs and G418
resistant. Evaluation of these spore clones by PCR amplification of an internal region
of the TOP2 gene demonstrated that these spore clones likely retained a second copy
of chromosome XIV due to chromosomal nondisjunction. These spore clones were
not included in the analysis.
Assessment of doubling time in S. cerevisiae. Diploid S. cerevisiae strains car-
rying wild-type or mutant TOP2 were grown in selective liquid culture to absor-
bance of 1.0 at O.D. 600. Serial absorbance measurements were taken hourly, and
doubling time calculated from the exponential growth phase. Growth studies were
performed five independent times.
Decatenation assay. S. cerevisiae strains carrying wild-type or mutant TOP2 were
grown to O.D. 600 2.5–3, and nuclei isolated per protocol http://www.biolchem.
ucla.edu/labs/grunstein/Yeast%20Nuclei%20Isolation.html, modified from Ponti-
celli and Struh67. Briefly, strains were grown to an O.D.600= 2.5–3, and resus-
pended in buffer (1M Sorbitol, 50 mM Tris pH 7.5, 10 mM MgCl2, 3 mM DTT)
and Zymolase (Zymo Research) added to a final concentration of 60 U/ml. Cells
were incubated at 30 °C with gentle shaking until 80% of cells formed ghosts.
Extracts were washed and spheroplasts resuspended in YPD with 1 M sorbitol
followed by washing with 1 M sorbitol. Extracts were mechanically homogenized in
Buffer N containing 25 mM K2SO4, 30 mM HEPES (pH 7.6), 5 mM MgSO4, 1 mM
EDTA, 10% glycerol and 0.1% NP-40 at 4 °C. The resulting homogenate was
centrifuged at 5000×g for 15 min at 4 °C. The supernatant was reserved and cen-
trifuged at 10,000×g for 25 min at 4 °C. The final pellet containing the isolated
nuclei was resuspended in 40 µl Buffer N, aliquoted and stored at −80 °C. Protein
concentrations were determined by Bradford assay (Bio-Rad) and 30 ng of extract
used in the assays. Nuclei were incubated with 500 ng kinetoplast DNA (Topogen,
Inc.) in the presence of ATP per instructions provided by Topogen, Inc. Reactions
were incubated at 37 °C for 60 min and terminated with loading dye. Reactions
were loaded in entirety on a 1% agarose+ 0.5 μg/ml ethidium bromide gel for
analysis of decatenation products, compared to the Topo II decatenated kDNA
marker (Topogen, Inc. TG2020-1). Band area was quantified using Image J. Three
independent assays were performed. A dilution assay using wild-type nuclear
extracts (2.5–40 ng) was performed to confirm the linearity of the assay, and linear
regression shown in Supplementary Fig. 4c.
Mouse models. Top2bflox2 mice were provided by Y.L. Lyu (via C-M Chuong, USC
Keck School of Medicine, Los Angeles, USA)68. As Top2b−/− mice are not viable21,
Top2bflox2 mice were bred to various mouse lines expressing conditional Cre
recombinase, to evaluate B-cell populations. Mice were bred to Cd79atm1(cre)Reth
(herein termed mb1-cre) kindly provided by M. Reth (University of Freiburg,
Germany)20 via R. Rickert (Prebys Medical Discovery Institute, La Jolla, USA)
or Cd19tm1(cre)Cgn mice (cd19-cre, The Jackson Laboratory, USA). Additionally,
Top2b+/EE587E mice were generated to express the delAGA mutation on mouse
Top2b (see below). All mice were between 12 and 22 weeks of age with age-
matching within each experiment; both male and female mice were used. No
additional randomization was performed, no animals excluded from analyses, and
no additional blinding performed. Experimental protocols were approved by the
Institutional Animal Care and Use Committee at the University of California,
San Diego.
Generation of Top2b−/− mb1-cre and Top2b−/− cd19-cre mice. Conditional
Top2b−/−mb1 and Top2b−/−cd19 mice were generated by breeding Top2bflox2/flox2
animals with mb1-cre or cd19-cre mice producing offspring that are Top2b+/Δ2mb1-
cre and Top2b+/Δ2cd19-cre, respectively. These mice were then crossed with
Top2bflox2/flox2 mice giving progeny of the desired genotypes; Top2bΔ2/Δ2mb1-cre
(Top2b−/−mb1) and Top2bΔ2/Δ2cd19-cre (Top2b−/−cd19). qPCR for Top2b
expression in isolated B cells confirmed an absence of Top2b expression (Source
data are provided in Source Data file).
Generation of Top2b+/delAGA knockin mice. A conditional by inversion
(COIN) allele to express the delAGA mutation on mouse Top2b, with the potential to
revert to wild-type sequence via inducible cre-lox technology, was created as follows: a
segment of human TOP2B containing the intron 13 splice acceptor (SA) region, exon
14, and intron 14 splice donor (SD) region was synthesized in reverse orientation
(reverse [TOP2B int13 SA-ex14-int14 SD]). This fragment was ligated to a synthetic
region consisting of the mouse Top2b intron 13 SA, exon 14 containing the del AGA
allele, and intron 14 SD, in forward orientation (forward [Top2b int13 SA-ex14 del
AGA-int14 SD]). To reduce the potential for hairpin formation between human and
mouse exon 14 base pair sequences, multiple silent mutations were included in the
reversed human exon 14. LoxP and Lox2372 recombination sites were interspersed
between human and mouse sequence, to mediate later COIN flipping and cre
recombinase-mediated deletion69. A reverse orientation neomycin phosphotransfer-
ase (npt) artificial minigene, flanked by flippase recognition target sites70, was ligated
5′ to the human segment. Expression of npt in mammalian cells was driven by the
promoter region of the human ubiquitin C (UBC) gene71 (coordinates
125398319:125399530 in the antisense strand of human chromosome 12; Human
CCDS set: CCDS9260), whereas expression in E. coli was driven by the EM7 promoter
(Invitrogen). The npt open reading frame was followed by the 3′ region of the mouse
Pgkl gene, containing a polyA signal and associated sequences (coordinates
103398979–103399440 of chromosome X), to ensure proper message termination. In
addition, Rox recombination sites72 were introduced to flank the npt minigene and
reverse [TOP2B int13 SA-ex14-int14 SD]. The final sequence of elements in the COIN
module is: loxP-Rox-Frt-reverse [UBC-neo-Pgkl polyA]-Frt-lox2372-reverse [TOP2B
int13 SA-ex14-int14 SD]-reverse (loxP)-Rox- forward [Top2b int13 SA-ex14 del
AGA-int14 SD]-reverse (lox2372).
The synthetic fragment described above was used to modify a mouse bacterial
artificial chromosome (BAC) using Velocigene technology73 and bacterial
homologous recombination74. The recombined BAC was sequence-verified,
linearized, and electroporated into mouse embryonic stem cells (F1H4:50% C57BL/
6NTac/50% 129S6/SvEvTac, Regeneron Pharmaceuticals). Appropriately targeted
stem cell clones were identified by loss of allele (LOA) assay73. The npt minigene
was then excised by Flpe75.
Qualitative rtPCR analysis on Flpe-treated stem cell clones showed a population
of COIN transcripts in which Top2b exon 14 (containing delAGA) was skipped. To
obtain a clean allele, the COIN module was excised using the Dre recombination
system, leaving exon 14 delAGA intact. The final allele is as follows: loxP-Rox-
forward [Top2b int13 SA-ex14 del AGA-int14 SD]-reverse (lox2372). Correctly
recombined ES cell clones were microinjected into 8-cell embryos from Charles
River Laboratories Swiss Webster albino mice, yielding F0 VelociMice® that were
100% derived from the targeted cells76. Resulting F0 mice were subsequently bred
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to C57BL/6NTac. Top2b+/delAGA knockin mice are owned by Regeneron
Pharmaceuticals, Inc., and any request for these mice should be directed to
Regeneron Pharmaceuticals, Inc.
Reverse transcription and quantitative PCR. RNA was isolated from trans-
formed S. cerevisiae, murine spleen, or murine bone marrow using Trizol (Life
Technologies) and cDNA was synthesized using Taqman Reverse Transcription
reagents (Applied Biosystems), both per manufacturer’s instructions. For kappa-
deleting recombination excision circles (KRECs)22, T-cell receptor excision circles,
and yeast strain plasmid number analyses, DNA was isolated using Trizol (Life
Technologies) or Qiagen’s yeast protocol, respectively. Quantitative PCR was
performed using 100 nM each forward and reverse primer and iQ SYBR Green
supermix (Bio-Rad) with a Bio-Rad CFX96 Real-Time System. Reaction para-
meters were as per Bio-Rad instructions with 3 min polymerase activation and
DNA desaturation (95 °C), denaturation for 15 s (95 °C) and annealing/extension
for 30 s at 55–60 °C, for 40 cycles. For KREC reactions, the cycle threshold was set
at 0.03, and the CT values of the coding joint and the signal joint compared for each
sample22. For TREC reactions, a dilution series of mTREC plasmid molecules was
used to establish a standard curve (100–10,000,000 molecules range), with
annealing/extension time increased to 1 min77. The mouse sjTREC standard was a
generous gift from Dr. Gregory D. Sempowski (Duke Human Vaccine Institute,
Durham, NC, USA). Sequences for qPCR primers are shown in Supplementary
Table 10. Data were visualized with CFX Manager v3.0 software.
Flow cytometry. Peripheral whole-mouse blood was obtained by cheek veni-
puncture, and collected in EDTA-treated collection tubes. Red cells were lysed
using ACK Lysing Buffer (ThermoFisher Scientific) per the manufacturer’s
instructions. Totally, 106 cells were stained with conjugated monoclonal antibodies
to CD3 (17A2, 17-0032-80, 1:200), CD19 (1D3, 12-0193-81, 1:400), and B220
(RA3-682, 11-0452-82, 1:200; all from eBioscience, Inc.; used per manufacturer’s
instructions). Murine spleens were mechanically dissociated and erythrocytes
removed by hypotonic lysis. 1 × 106 cells were stained with conjugated monoclonal
antibodies to CD19 (1D3, 12-0193-81, 1:400), B220 (RA3-682, BioLegend, 130-
102-357, 1:50), IgM (121-15F9, 48-5890-82, 1:100), IgD (11-26, 17-5993-80, 1:200),
Flt3 (A2F10, 46-1351-82, 1:100), GL-7 (GL-7, 53-5902-80, 1:200), CD23 (B3B4, 12-
0232-81, 1:200), CD38 (90, 12-0381-81, 1:200), CD21/35 (8D9, 47-0211-80, 1:100),
MHC class II (M5/114.15.2, 12-5321-81, 1:100), CXCR4 (2B11, 147-9991-80,
1:200), (all from eBioscience, Inc., unless otherwise noted) per manufacturer’s
instructions. Bone marrow cells were harvested from femurs and tibiae by flushing
with PBS, and similarly stained with CD19 (1D3, 17-0193-80, 1:400), B220 (RA3-
682, BioLegend, 130-102-357, 1:50), IgM (121-15F9, 48-5890-82, 1:100), CXCR4
(2B11, 147-9991-80, 1:200), Flt3 (A2F10, 46-1351-82, 1:100), CD43 (R2/60, 11-
0431-81, 1:200), BP-1 (6C3, 12-5891-81, 1:200), CD25 (PC61.5, 61-0251-80, 1:200),
CD24 (M1/69, 25-0242-80, 1:200) (all from eBioscience, Inc., unless otherwise
noted). CFSE [5-(and 6)-carboxyfluorescein diacetate succinimidyl ester]
staining was performed per manufacturer’s protocol (eBioscience, Inc.).
Samples were acquired with a BD Biosciences LSR II cytometer using FACSDiva
software, and analyzed with FlowJo V10 software. Gating strategy is shown in
Supplementary Fig. 978.
Immunocytochemistry. For histological analysis, spleens were removed and post-
fixed in 4% paraformaldehyde in 0.1M PBS (pH 7.4) overnight at 4 °C, then
cryoprotected for 24 h at 4 °C in 0.1M phosphate buffer containing 20% sucrose.
Sections measuring 30 μm thick were cut at −18 °C on a cryostat microtome
(Cryocut, 1800), and collected free-floating in 0.1M PBS containing 0.02% sodium
azide. The spleen sections were first incubated for 60min at room temperature in
0.1M PBS containing 5% normal donkey serum and 0.8% Triton X-100. Sections
were then incubated overnight at 4 °C with primary antibodies diluted in same
solution used for pre-incubation. In order to perform triple immunolabeling, the
following directly conjugated primary antibodies were used: (1) anti-CD3 (10 µg/mL,
Alexa Fluor 488, clone 17A2, Biolegend, 100210), (2) anti-B220 (1 µg/mL, eFluor®
570 CD45R, clone RA3-6B2, eBioscience, Inc., 41-0452-80), and (3) anti-CD169 (5
µg/mL, Alexa Fluor 647, clone 3D6.112, BioLegend, Inc., 142408). The following
isotype controls: (1) Alexa Fluor 488 Rat IgG2b, kappa (BioLegend, Inc., 400625), (2)
eFluor 570 Rat IgG2a, kappa (ThermoFisher Scientific, Inc., 41-4321-82), and (3)
Alexa Fluor 647 Rat IgG2a, kappa (BioLegend, Inc., 400526) antibodies were used
for the negative control staining. 4′-6-diamidino-2-phenylindole (DAPI, 4 μg/mL,
D3571, Invitrogen) was used for general nuclear staining of all sections. After
washing three times for 10min with PBS, sections were mounted on slides, air-dried,
and then cover-slipped with ProLong Gold (ThermoFisher Scientific, Inc.).
Image processing and quantitative assessment. The quantitative analysis uti-
lized 4 age-matched control and 4 Top2b−/− mb1 cre mice. The sizes of the splenic
white pulp and its three sub-compartments were evaluated in at least ten follicles
across three sections (500 μM apart) per mouse. The triple labeled sections
visualizing CD3, B220, and CD169 positive cells were scanned via confocal
microscopy (LSM 710 NLO Zeiss; ZEN 2010). The marginal zone (MZ), which
contains B220-positive B cells and CD169-positive metallophilic macrophages, the
transitional B-cell rich follicular region (FR) and CD3-positive T-cell rich
periarteriolar lymphoid sheath subcompartments were measured by Image Pro-
Plus (Media Cybernetics) software. All histological and image analyses were per-
formed by blinded investigator.
Immunizations. For ovalbumin immunizations, adult mice aged 12–22 weeks were
immunized intraperitoneally with 50 μg of OVA (Worthington Biochemical)
adsorbed to 1 mg of alum (Sigma-Aldrich) in 200 μl normal saline, administered as
2 injections given 7 days apart79. Seven days after the second injection, mice were
anesthetized (ketamine 60 mg/kg plus xylazine 10 mg/kg intraperitoneally), the
peritoneal and thoracic cavities opened, and blood samples obtained via cardiac
puncture. Immunizations were performed in 3–4 independent experiments to
permit age-matching within each experiment, with mice from two litters per
experiment. Immunizations with Pneumovax®23 were performed by immunizing
adult mice intraperitoneally once with 10 µl of Pneumovax®23 in 100 µl sterile
PBS27. Mice were bled 24 h prior, and 6 and 42 days after immunization. Serum
was isolated, and ELISAs performed as described below.
Enzyme-linked immunosorbent assay (ELISA). Total mouse IgG was assessed
using the Ready-Set-Go® kit (ThermoFisher Scientific, Inc.) per manufacturer’s
protocol. Quantification of OVA-IgG (Cayman Chemical, Ann Arbor, MI, USA)
was performed by ELISA according to manufacturer’s instruction. Anti-Pneumo-
vax®23 IgM and IgG subclass ELISAs were performed by coating Nunc ELISA
plates with 5 μl Pneumovax® 23 in 50 μl PBS overnight. Plates were blocked for 2 h
with 1% BSA, 0.1% sodium azide in PBS before adding 50 μl of diluted serum (1:80)
to each well. After a 2 h incubation, anti-mouse IgM-HRP (1:1000, Thermo-
Scientific, 62–6820), goat anti-mouse IgG3 (1:1000, ThermoScientific, M32707) or
goat anti-mouse IgG2b (1:1000, ThermoScientific, M32407) were added for 2 h,
followed by TMB substrate. Absorbance was measure at 450 nm27. Measurement of
mouse IL-2 was performed by ELISA (R and D Systems) according to manu-
facturer’s instruction.
Cell isolations. Magnetic bead isolation of cells from murine bone marrow and
spleens was performed with the following Miltenyi Biotec kits: anti-B220
microbeads, Pan T-cell isolation kit, CD138+ microbeads, direct lineage depletion
kit, CD117 microbeads, and anti-rat IgG microbeads. In all cases, isolations were
performed per manufacturer’s protocol.
Lymphocyte stimulation assays. B cells were isolated from murine spleens using
anti-B220 magnetic beads per manufacturer’s protocol (Miltenyi Biotec) with >98%
purity achieved. B cells were washed and then cultured in triplicate at 5 × 104 cells/
mL in RPMI 1640+ 10% fetal bovine serum, with 25 μg/mL LPS (E. coli 0111:B4,
Calbiochem) with or without recombinant mouse IL-4 (10 ng/mL, Life Technol-
ogies)80. Cell counts were performed at day 3 of stimulation using BioRad TC20
automated cell counter. Supernatants were collected for measurement of immu-
noglobulins (see ELISA section above), or LDH release per manufacturer’s protocol
(Pierce LDH Cytotoxicity Assay Kit, ThermoScientific). A subset was stained with
CFSE [5-(and 6)-carboxyfluorescein diacetate succinimidyl ester] per manu-
facturer’s protocol (eBioscience, Inc.).
T cells were isolated from murine spleens using Pan T-cell isolation magnetic
beads per manufacturer’s protocol (Miltenyi Biotec) with >98% purity achieved.
T cells were washed and then cultured at 106 cells/mL in RPMI 1640+ 10% fetal
bovine serum and stimulated with 20 ng/mL phorbol 12-myristate 13-acetate
(PMA) and 1 μg/mL ionomycin. Supernatants were collected for measurement of
IL-2 (see ELISA section above).
Comet assay. A neutral comet assay was performed as described by Olive and
Banath81 with the following modifications. Frosted end microscope slides were
washed, rinsed in methanol, and coated with 1% normal melting temperature
agarose. After cooling, 4 × 105 splenic B or T cells (isolated as above) were
resuspended in 1% low-gelling temperature agarose, and applied to precoated
slides. Cells were lysed in buffer containing 2% sarkosyl, 0.5 M Na2EDTA and
0.05% Triton-X at 4 °C for 1 h, followed by electrophoresis in Tris/Borate/EDTA
buffer for 25 min at 0.6 V/cm. Slides were stained with 10 μg/mL propidium iodide.
Fluorescent images were immediately acquired using a Leica TCS SPE laser-
scanning confocal microscope at ×40 magnification (Leica Microsystems, Buffalo
Grove, IL), with at least 5 fields and 50 cells captured per sample. Comet head and
tail length were measured with ImageJ software.
Immunoblot. B and T cells were isolated from wild-type spleens using magnetic
beads as above. Cell lysates were prepared from 3 × 106 cells by incubating with lysis
buffer (50mM Tris HCl pH 7.8, 150mM NaCl, 0.1% NP-40, 1 mM PMSF) and
denatured in Laemmli buffer (Bio-Rad, Inc.) with 355mM 2-mercaptoethanol. After
boiling, proteins were separated by SDS-polyacrylamide gel electrophoresis, trans-
ferred to polyvinylidene fluoride membranes, and immunoblotted with mouse
monoclonal antibody to Top2b (1 μg/mL, ThermoFisher Scientific, MA5-24310)
followed by horseradish-peroxidase conjugated anti-mouse (7076S, Cell Signaling
Technology, Inc.), for detection by chemiluminescence (ThermoFisher Scientific).
Anti-GAPDH-HRP was used to assess gel loading (1:3000, Proteintech, HRP-60004).
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Statistical analyses. Statistical analyses and graphing were performed in Micro-
soft Excel and Graphpad Prism (version 5.03; Graph Pad, Graph Pad Software Inc.,
CA) programs with the two-tailed, unpaired Student's t test, or the Kruskal–Wallis
test, in all cases comparing wild-type vs. mutant. Flow cytometry data were ana-
lyzed by FlowJo software. Data are expressed as mean ± SEM. No samples or
animals were excluded from the analyses, and no randomizations performed. A p
value less than 0.05 was considered statistically significant.
URLs. For Burrows–Wheeler aligner and Picard, see http://broadinstitute.github.io/
picard/; for Genome Analysis Toolkit (GATK), see https://software.broadinstitute.
org/gatk/.
Reporting summary. Further information on research design is available in
the Nature Research Reporting Summary linked to this article.
Data availability
The authors declare that the data supporting the findings of this study are available
within the paper and its Supplementary Information. Data contained in ChIP-seq and
End-seq BED files (available from GEO, accession GSE99197)48 were visualized using the
Integrated Genomics Viewer (IGV 2.4.8) Broad Institute. Genome and exome data for
individual patients cannot be made publicly available for reasons of patient
confidentiality. Qualified researchers may apply for access to these data, pending
University of California, and CHOP institutional review board approval. Source data for
Figs. 2d and 6i are included in the Source Data file.
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